
Generate Biomedicines fell 17.1% from $12.65 to $10.49, behind the S&P 500's +7.9%. Its worst day was Aug 26 (−20.8%), and its low came Nov 16 at $10.49.
Feb 27, 2026 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-1.07 missed the $-0.48 estimate on $7.2M revenue (est. $6.0M).
−11.2% · S&P 500 −0.3%
Story events cover the past 12 months · Times ET
Generate Biomedicines shares fell 18.7%, while the S&P 500 fell 0.1%.
−18.7% · S&P 500 −0.1%
EPS of $-0.52 missed the $-0.49 estimate on $6.3M revenue (est. $5.5M).
−4.1% · S&P 500 −0.2%
Generate Biomedicines closed at its highest level of the year, 61.1% above where the year started.
+15.0% · S&P 500 +0.3%
Generate Biomedicines shares rose 16.4%, while the S&P 500 rose 0.3%.
+16.4%, the year's best day · S&P 500 +0.3%
EPS of $-0.68 missed the $-0.54 estimate on $4.2M revenue (est. $7.8M).
−6.8% · S&P 500 −0.4%
Where it ended: a close of $10.49 on Nov 16, 2026. Up next: Q4 2026 earnings on Feb 3, 2027 (EPS est. $-0.65, revenue est. $6.8M).
Nothing in the past 12 months.
All GENB dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for GENB and SPY from Benzinga historical bars. Not investment advice.